Antidepressants fall into several distinct classes — SSRIs, SNRIs, TCAs, MAOIs, and atypicals — each targeting different neurotransmitter systems, which explains their varying side-effect profiles and why one may work when another doesn't. SSRIs and SNRIs are the most commonly prescribed today because they have a more tolerable side-effect profile than older TCAs or MAOIs. All antidepressants typically take 2–6 weeks to show therapeutic effect, and stopping abruptly can cause discontinuation syndrome — always taper under medical supervision.
Antidepressants 101: SSRIs, SNRIs, and How They Differ
Antidepressants are among the most prescribed medications in the United States — tens of millions of people take them — yet they remain widely misunderstood. Many patients don't know which class they're taking, why their doctor chose it over another, or what to do when it stops working or causes side effects. This guide walks through the five main categories, what distinguishes each, and a few things that commonly catch people off guard.
SSRIs: The First-Line Standard
Selective serotonin reuptake inhibitors are where virtually every clinician starts for uncomplicated depression or anxiety. The mechanism: serotonin is a neurotransmitter released between nerve cells. After it crosses the synapse, the sending neuron normally reabsorbs (reuptakes) most of it. SSRIs block that reabsorption, leaving more serotonin available in the synaptic gap. Over time, this appears to support mood regulation — though the full picture of how antidepressants work is considerably more complex than the simple "low serotonin = depression" story that was popular in the 1990s.
The most prescribed SSRIs include fluoxetine (Prozac), sertraline (Zoloft), and escitalopram (Lexapro). They share a generally favorable side effect profile: most common are nausea (usually transient in the first week or two), headache, and sexual dysfunction — reduced libido and delayed or absent orgasm — which is the side effect people are least likely to volunteer but most likely to find distressing. SSRIs are also associated with weight gain over the long term, more than initial trials suggested. Fluoxetine has the longest half-life of the class (weeks rather than days), which means missed doses matter less and stopping it produces fewer withdrawal effects.
SNRIs: Adding Norepinephrine
Serotonin-norepinephrine reuptake inhibitors work identically to SSRIs for serotonin, but also block the reuptake of norepinephrine, a neurotransmitter involved in alertness, energy, and the body's stress response. Venlafaxine (Effexor) and duloxetine (Cymbalta) are the most commonly prescribed.
The dual action makes SNRIs particularly useful when depression co-occurs with chronic pain, anxiety disorders, or fibromyalgia. Duloxetine is FDA-approved for diabetic peripheral neuropathy and musculoskeletal pain — so a patient taking it for back pain and depression is getting one drug doing two jobs. The side effect profile is similar to SSRIs with the addition of elevated blood pressure and heart rate at higher doses due to the norepinephrine component. Venlafaxine in particular carries a reputation for a difficult discontinuation syndrome — more on that below.
TCAs: Older, Broader, and Less Convenient
Tricyclic antidepressants — amitriptyline, nortriptyline, clomipramine — were the dominant treatment for depression before SSRIs arrived in the late 1980s. They also block serotonin and norepinephrine reuptake, but do so less selectively, hitting a wide range of other receptors in the process. That broad action is responsible for their side effect burden: dry mouth, constipation, urinary retention, blurred vision, sedation, and significantly elevated risk of dangerous cardiac arrhythmias in overdose.
TCAs have largely been displaced for primary depression treatment, but they remain valuable in specific niches: amitriptyline at low doses (10–25 mg) is widely used for migraine prevention, tension headache, and neuropathic pain, often at doses too low to produce antidepressant effects but high enough to modulate pain signaling. For chronic pain patients who haven't responded to other approaches, they're still a genuinely useful option.
MAOIs: Effective but Demanding
Monoamine oxidase inhibitors — phenelzine, tranylcypromine — were the first antidepressants, discovered in the 1950s. They work by blocking the enzyme that breaks down serotonin, norepinephrine, and dopamine, leaving all three elevated. They're effective, sometimes dramatically so for patients who haven't responded to anything else, but they come with a serious and non-negotiable dietary constraint: avoiding foods high in tyramine (aged cheeses, cured meats, fermented foods, certain wines) while taking them. Without that enzyme to break tyramine down, ingesting it can cause a hypertensive crisis — a sudden, dangerous spike in blood pressure.
Drug interactions are also extensive: combining an MAOI with another serotonergic drug risks serotonin syndrome, a potentially life-threatening condition. For these reasons, MAOIs are rarely prescribed today — typically reserved for treatment-resistant depression managed by a specialist. They require patients who are meticulous, educated, and closely supervised.
Atypicals: A Varied Category
The "atypical" label is a catch-all for antidepressants that don't fit neatly into the above classes. Two stand out for practical importance. Bupropion (Wellbutrin) blocks the reuptake of dopamine and norepinephrine, with no meaningful effect on serotonin. This gives it a distinct profile: it tends to be activating rather than sedating, causes minimal to no sexual dysfunction (making it a common add-on for patients troubled by that SSRI side effect), and is FDA-approved for smoking cessation under the brand name Zyban. It lowers the seizure threshold at high doses, so it's not appropriate for patients with eating disorders or seizure history.
Mirtazapine works through a completely different mechanism — blocking certain norepinephrine and serotonin autoreceptors as well as histamine receptors. The histamine blockade makes it strongly sedating, and the receptor profile stimulates appetite. For a patient with depression presenting with insomnia and significant weight loss, mirtazapine addresses all three issues simultaneously. It's not a drug for someone struggling with obesity or insomnia caused by something other than depression, but in the right patient it's a clinically elegant choice.
The 4–6 week delay before antidepressants take effect isn't because the drug takes that long to reach therapeutic levels in the blood — most SSRIs achieve steady-state within a week. The delay reflects the time needed for downstream receptor adaptation: the brain gradually adjusts the density and sensitivity of serotonin receptors in response to sustained increased serotonin availability. The drug is working from day one; the brain is catching up.
Antidepressant Comparison
| Class | Examples | Mechanism | Notable Side Effects | Best For |
|---|---|---|---|---|
| SSRI | Fluoxetine, Sertraline, Escitalopram | Block serotonin reuptake | Sexual dysfunction, nausea, weight gain | First-line depression and anxiety |
| SNRI | Venlafaxine, Duloxetine | Block serotonin + norepinephrine reuptake | Elevated BP, sweating, hard to stop | Depression with pain or anxiety |
| TCA | Amitriptyline, Nortriptyline | Broad reuptake inhibition | Dry mouth, sedation, cardiac risk in OD | Pain, migraine prevention |
| MAOI | Phenelzine, Tranylcypromine | Block MAO enzyme | Tyramine crisis risk, many drug interactions | Treatment-resistant depression |
| Atypical | Bupropion, Mirtazapine | Various | Bupropion: seizure risk at high dose. Mirtazapine: sedation, weight gain | Smoking cessation, insomnia + depression |
Discontinuation Syndrome
Stopping antidepressants — particularly venlafaxine and paroxetine — abruptly can produce a cluster of unpleasant symptoms: dizziness, irritability, flu-like aching, and a striking sensation commonly described as "brain zaps," brief electrical-jolt feelings in the head. This is discontinuation syndrome, not addiction or withdrawal in the traditional sense. The brain has adapted to a new serotonin environment and needs time to re-adapt when the drug is removed. Tapering the dose slowly over weeks or months virtually eliminates these symptoms. If your prescriber is recommending stopping an antidepressant, ask about a taper schedule — there's rarely a reason to stop quickly.
Never stop an antidepressant abruptly without discussing it with your prescriber. Discontinuation syndrome can begin within 24–72 hours of a missed dose — especially with venlafaxine, which has a short half-life. A slow taper is almost always the right approach.
Frequently Asked Questions
How long do antidepressants take to work?
Most antidepressants take 2–6 weeks before significant therapeutic benefit is apparent. This delay doesn't reflect how long the drug takes to reach stable blood levels — most SSRIs achieve that within a week. The delay reflects the time required for the brain to adapt its receptor density and sensitivity in response to sustained changes in neurotransmitter availability. Patience is important; many people discontinue effective treatment too early.
What is the difference between SSRIs and SNRIs?
SSRIs (selective serotonin reuptake inhibitors) block the reuptake of serotonin only, while SNRIs (serotonin-norepinephrine reuptake inhibitors) block the reuptake of both serotonin and norepinephrine. The added norepinephrine activity in SNRIs can provide benefits for patients with chronic pain, fatigue, and anxiety alongside depression. Duloxetine (Cymbalta) is FDA-approved specifically for diabetic peripheral neuropathy and musculoskeletal pain in addition to depression.
What happens if you stop taking antidepressants suddenly?
Abruptly stopping antidepressants — particularly SNRIs like venlafaxine, or paroxetine among SSRIs — can cause discontinuation syndrome: flu-like symptoms, dizziness, electric shock-like sensations ("brain zaps"), irritability, and mood disturbance. These are not signs of addiction; they reflect the nervous system adjusting after removing a drug it has adapted to. Tapering gradually under medical supervision is the standard way to discontinue antidepressants safely.
Do antidepressants cause weight gain?
Some do, some are relatively neutral, and one tends to cause weight loss. Most SSRIs and SNRIs are associated with modest weight gain with long-term use, more than short-term clinical trials suggested. Mirtazapine causes the most pronounced weight gain due to its histamine-blocking activity and appetite stimulation. Bupropion (Wellbutrin) is the notable outlier — it tends to be weight-neutral or associated with mild weight loss, which makes it a common choice for patients concerned about this side effect.
Need to identify an antidepressant by its imprint or look up its side effects?
Look Up Side Effects